Trial
NCT01312818
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
Millennium Pharmaceuticals, Inc.
Condition
Acute Lymphoblastic Leukemia
Intervention
Bortezomib
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-28